{
    "clinical_study": {
        "@rank": "13088", 
        "arm_group": {
            "arm_group_label": "Dose escalation", 
            "arm_group_type": "Experimental", 
            "description": "For the Phase I arm of the study the addition of planned numbers and ratios of Treg compared to Tcon will occur at defined time points after hematopoietic cell infusion. Each cohort will have 3 patients per group. The initial doses and ratios utilized will be 1 x 10^6/kg of T reg cells to 3x10^6/kg of Tcon cells at a 1:3 ratio. In order to progress to the next dose level, there must be no evidence of grade 3 or 4 acute GVHD."
        }, 
        "brief_summary": {
            "textblock": "For patients with hematologic malignancies undergoing allogeneic myeloablative (MA) HCT with\n      a T cell depleted graft, the infusion of naturally occurring regulatory T cells  with\n      conventional T cells  (T cell addback) in pre-defined doses and ratios will reduce the\n      incidence of acute graft vs host disease while augmenting the graft vs leukemia effect and\n      improving immune reconstitution."
        }, 
        "brief_title": "Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myeloid Leukemia, Chronic", 
            "Acute Myelogenous Leukemia", 
            "Myelodysplastic Syndromes (MDS)", 
            "Lymphoma, Non-Hodgkin"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Chronic Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Recipient Inclusion Criteria:\n\n          -  Patients with the following diseases that are histopathologically confirmed are\n             eligible\n\n               -  Acute leukemia, primary refractory or beyond CR1\n\n               -  Chronic myelogenous leukemia (accelerated, blast or second chronic phase)\n\n               -  Myelodysplastic syndromes\n\n               -  Non-Hodgkin lymphoma with poor risk features not suitable for autologous HCT\n\n          -  Age <= 60 yo\n\n          -  Cardiac ejection fraction >= 45%\n\n          -  Lung diffusion capacity >= 50%\n\n          -  Calculated creatinine clearance  >= 50 cc/min\n\n          -  SGPT  and SGOT <=  2.5 x ULN, unless elevated secondary to disease. Total bilirubin\n             <= 2 x ULN (patients with Gilbert's syndrome may be included at the discretion of the\n             PI or where hemolysis has been excluded\n\n          -  Availability of a 6/6 HLA matched sibling defined by Class I (HLA -A and B) serologic\n             typing (or higher resolution) and Class II (HLA-DRB1) molecular typing.\n\n          -  Karnofsky performance status >=70%\n\n          -  No prior myeloablative therapy or hematopoietic cell transplantation\n\n        Recipient Exclusion Criteria\n\n          -  Seropositive for any of the following: HIV ab, hepatitis B sAg , hep C ab\n\n          -  Uncontrolled bacterial, viral or fungal infection defined as currently taking\n             antimicrobial therapy and progression of clinical symptoms.\n\n          -  Uncontrolled CNS disease involvement\n\n          -  The recipient is pregnant or a lactating female\n\n          -  Psychosocial circumstances that preclude the patient being able to go through\n             transplant or participate responsibly in follow up care.\n\n        Donor Inclusion Criteria\n\n          -  Age <= 75 years\n\n          -  Karnofsky performance status of >=70%\n\n          -  Medical history and PE confirm good health status as defined by institutional\n             standards\n\n          -  Seronegative for HIV Ag, HIV 1 and HIV 2 ab, HTLV 1 and HTLV 2 ab hepatitis B sAg or\n             PCR+ or  hepatitis C ab or PCR+ , negative for the Syphilis treponemal screen and\n             negative for HIV 1 and hepatitis C by NAT (nucleic acid testing) within 30 days of\n             apheresis collection\n\n          -  Must be 6/6 matched sibling donor as determined by HLA typing\n\n          -  Female donors of child-bearing potential must have a negative serum or urine beta-HCG\n             test within three weeks of mobilization\n\n          -  Capable of undergoing leukapheresis, have adequate venous access, and be willing to\n             undergo insertion of a central catheter should leukapheresis via peripheral vein be\n             inadequate\n\n          -  The donor or legal guardian greater than 18 years of age, capable of signing an\n             IRB-approved consent form.\n\n        Donor Exclusion Criteria\n\n          -  Evidence of active infection or viral hepatitis\n\n          -  HIV positive\n\n          -  Lactating female"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660607", 
            "org_study_id": "BMT236", 
            "secondary_id": "SU-09142011-8407"
        }, 
        "intervention": {
            "arm_group_label": "Dose escalation", 
            "description": "A baseline cell dose of conventional T cells of 1x10^6/kg will be used with escalation to the maximum tolerated dose up to 1x10^7/kg", 
            "intervention_name": "Conventional T cells (Tcon) and Regulatory T cells (Treg)", 
            "intervention_type": "Biological", 
            "other_name": "Purified regulatory T cells"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 31, 2013", 
        "location": {
            "contact": {
                "email": "ginna.laport@stanford.edu", 
                "last_name": "Ginna G Laport", 
                "phone": "650-723-0822"
            }, 
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University School of Medicine Palo Alto, California, United States"
            }, 
            "investigator": [
                {
                    "last_name": "Rajni Agarwal-Hashmi", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sally Arai", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jonathan Benjamin", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Laura Johnston", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert Lowsky", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert S Negrin", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kevin Sheehan", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Judith Anne Shizuru", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "David Miklos", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Wen-Kai Weng", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I/II Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T Cell Depleted Graft With Simultaneous Infusion of Conventional T Cells and Regulatory T Cells", 
        "overall_contact": {
            "email": "lpeysakh@stanford.edu", 
            "last_name": "Lana Peysakhovich", 
            "phone": "650-721-3253"
        }, 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Ginna G Laport", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "(Phase II) Event free survival post-HCT", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660607"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Ginna Laport", 
            "investigator_title": "Assoc Prof-Med Ctr Line", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institutes of Health (NIH)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Ginna Laport", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}